Advanced search
Publication Cover
Pharmacogenomics Volume 17, 2016 - Issue 15
Submit an article Journal homepage
2,105
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Capecitabine Pharmacogenetics: Historical Milestones and Progress Toward Clinical Implementation

Nicholas Syn1 Department of Haematology-Oncology, National University Cancer Institute, Singapore119228;2 Cancer Science Institute of Singapore, National University of Singapore, Singapore117599;3 Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore117600View further author information
,
Soo-Chin Lee1 Department of Haematology-Oncology, National University Cancer Institute, Singapore119228;2 Cancer Science Institute of Singapore, National University of Singapore, Singapore117599View further author information
,
Boon-Cher Goh1 Department of Haematology-Oncology, National University Cancer Institute, Singapore119228;2 Cancer Science Institute of Singapore, National University of Singapore, Singapore117599;3 Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore117600View further author information
&
Wei-Peng Yong1 Department of Haematology-Oncology, National University Cancer Institute, Singapore119228;2 Cancer Science Institute of Singapore, National University of Singapore, Singapore117599Correspondence[email protected]
View further author information
Pages 1607-1610 | Received 28 Jul 2016, Accepted 28 Jul 2016, Published online: 27 Sep 2016

References

  • Midgley R , KerrDJ . Capecitabine: have we got the dose right?Nat. Clin. Pract. Oncol.6 ( 1 ), 17 – 24 ( 2009 ).
  • Cunningham D , StarlingN , RaoSet al. Capecitabine and oxaliplatin for advanced esophagogastric cancer . N. Engl. J. Med.358 ( 1 ), 36 – 46 ( 2008 ).
  • Kang Y-K , KangW-K , ShinD-Bet al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised Phase III noninferiority trial . Ann. Oncol.20 ( 4 ), 666 – 673 ( 2009 ).
  • Haller DG , CassidyJ , ClarkeSJet al. Potential regional differences for the tolerability profiles of fluoropyrimidines . J. Clin. Oncol.26 ( 13 ), 2118 – 2123 ( 2008 ).
  • Mackean M , PlantingA , TwelvesCet al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer . J. Clin. Oncol.16 ( 9 ), 2977 – 2985 ( 1998 ).
  • Van Cutsem E , FindlayM , OsterwalderBet al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized Phase II study . J. Clin. Oncol.18 ( 6 ), 1337 – 1345 ( 2008 ).
  • Hennessy BT , GauthierAM , MichaudLBet al. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature . Ann. Oncol.16 ( 8 ), 1289 – 1296 ( 2005 ).
  • Syn NL-X , YongW-P , LeeS-Cet al. Genetic factors affecting drug disposition in Asian cancer patients . Expert Opin. Drug Metab. Toxicol.11 ( 12 ), 1879 – 1892 ( 2015 ).
  • Schwab M , ZangerUM , MarxCet al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group . J. Clin. Oncol.26 ( 13 ), 2131 – 2138 ( 2008 ).
  • Meulendijks D , HenricksLM , SonkeGSet al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data . Lancet Oncol.16 ( 16 ), 1639 – 1650 ( 2015 ).
  • Terrazzino S , CargninS , Del ReMet al. DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis . Pharmacogenomics14 ( 11 ), 1255 – 1272 ( 2013 ).
  • Rosmarin D , PallesC , ChurchDet al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis . J. Clin. Oncol.32 ( 10 ), 1031 – 1039 ( 2014 ).
  • Caudle KE , ThornCF , KleinTEet al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing . Clin. Pharmacol. Ther.94 ( 6 ), 640 – 645 ( 2013 ).
  • Swen JJ , NijenhuisM , de BoerAet al. Pharmacogenetics: from bench to byte – an update of guidelines . Clin. Pharmacol. Ther.89 ( 5 ), 662 – 673 ( 2011 ).
  • Henricks LM , LunenburgCATC , MeulendijksDet al. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score . Pharmacogenomics16 ( 11 ), 1277 – 1286 ( 2015 ).
  • Loganayagam A , Arenas HernandezM , CorriganAet al. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity . Br. J. Cancer108 ( 12 ), 2505 – 2515 ( 2013 ).
  • Marsh S , Collie-DuguidESR , LiTet al. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations . Genomics58 ( 3 ), 310 – 312 ( 1999 ).
  • Soo RA , SynN , LeeS-Cet al. Pharmacogenetics-guided Phase I study of capecitabine on an intermittent schedule in patients with advanced or metastatic solid tumours . Sci. Rep.6 , 27826 ( 2016 ).
  • Marsh S , McKayJA , CassidyJ , McLeodHL . Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer . Int. J. Oncol.19 ( 2 ), 383 – 386 ( 2001 ).
  • Yap YS , KwokL-L , NgRCHet al. Predictors of hand–foot syndrome (HFS) in randomised double-blind, placebo-controlled trial of pyridoxine for prevention of capecitabine induced HFS . ASCO Meet. Abstr.33 , 9596 ( 2015 ).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.